{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:48:21Z","timestamp":1791931701954,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006022","name":"French Government Ministry of Social Affairs Health and Womens Rights","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.nbd.2021.105311","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T05:48:21Z","timestamp":1614059301000},"page":"105311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia"],"prefix":"10.1016","volume":"153","author":[{"given":"Giulia","family":"Coarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Darios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilien","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Dorgham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Adanyeguh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Mochel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Durr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2021.105311_bb0005","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.nicl.2018.06.011","article-title":"Autosomal dominant cerebellar ataxias: imaging biomarkers with high effect sizes","volume":"19","author":"Adanyeguh","year":"2018","journal-title":"NeuroImage Clin."},{"issue":"1","key":"10.1016\/j.nbd.2021.105311_bb0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ana.25276","article-title":"Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion","volume":"84","author":"Benatar","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2021.105311_bb0015","article-title":"Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer\u2019s disease","volume":"19","author":"Benedet","year":"2020","journal-title":"Brain J Neurol. Published online November"},{"issue":"1","key":"10.1016\/j.nbd.2021.105311_bb0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum Neurofilament light chain levels in patients with Presymptomatic multiple sclerosis","volume":"77","author":"Bjornevik","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2021.105311_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid Neurofilament light protein in neurology: a systematic review and meta-analysis","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.nbd.2021.105311_bb0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2021.105311_bb0035","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3389\/fneur.2017.00485","article-title":"Peripheral oxidative stress biomarkers in Spinocerebellar Ataxia type 3\/Machado-Joseph disease","volume":"8","author":"de Assis","year":"2017","journal-title":"Front. Neurol."},{"issue":"Pt 5","key":"10.1016\/j.nbd.2021.105311_bb0040","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/brain\/awn059","article-title":"Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment","volume":"131","author":"du Montcel","year":"2008","journal-title":"Brain J. Neurol."},{"issue":"21","key":"10.1016\/j.nbd.2021.105311_bb0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123193","article-title":"Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles","volume":"3","author":"Friedrich","year":"2018","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.nbd.2021.105311_bb0050","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"15","key":"10.1016\/j.nbd.2021.105311_bb0055","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/mds.22288","article-title":"Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6","volume":"23","author":"Globas","year":"2008","journal-title":"Mov Disord Off J Mov Disord Soc."},{"key":"10.1016\/j.nbd.2021.105311_bb0060","article-title":"PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study","volume":"26","author":"Gonsior","year":"2020","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.nbd.2021.105311_bb0065","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch. Neurol."},{"issue":"10","key":"10.1016\/j.nbd.2021.105311_bb0070","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.nbd.2021.105311_bb0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fneur.2015.00091","article-title":"CSF Neurofilament light chain but not FLT3 ligand discriminates Parkinsonian disorders","volume":"6","author":"Herbert","year":"2015","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.nbd.2021.105311_bb0080","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1474-4422(13)70104-2","article-title":"Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data","volume":"12","author":"Jacobi","year":"2013","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.nbd.2021.105311_bb0085","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","article-title":"Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study","volume":"14","author":"Jacobi","year":"2015","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.nbd.2021.105311_bb0090","doi-asserted-by":"crossref","first-page":"e717","DOI":"10.1212\/WNL.0000000000005005","article-title":"Neurofilament light protein in blood predicts regional atrophy in Huntington disease","volume":"90","author":"Johnson","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.nbd.2021.105311_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.nbd.2021.105311_bb0100","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"issue":"10","key":"10.1016\/j.nbd.2021.105311_bb0105","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.nbd.2021.105311_bb0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13024-019-0338-0","article-title":"Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3","volume":"14","author":"Li","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"22","key":"10.1016\/j.nbd.2021.105311_bb0115","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.nbd.2021.105311_bb0120","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma Neurofilament light and Neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.nbd.2021.105311_bb0125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ana.25264","article-title":"Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice","volume":"84","author":"McLoughlin","year":"2018","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.nbd.2021.105311_bb0130","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/acn3.325","article-title":"Neurofilament light chain: a biomarker for genetic frontotemporal dementia","volume":"3","author":"Meeter","year":"2016","journal-title":"Ann Clin Transl Neurol."},{"key":"10.1016\/j.nbd.2021.105311_bb0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","article-title":"Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models","volume":"7","author":"Moore","year":"2017","journal-title":"Mol Ther Nucleic Acids."},{"issue":"465","key":"10.1016\/j.nbd.2021.105311_bb0140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap8677","article-title":"Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7","volume":"10","author":"Niu","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.nbd.2021.105311_bb0145","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mds.27897","article-title":"CSF or serum neurofilament light added to \u03b1-Synuclein panel discriminates Parkinson\u2019s from controls","volume":"35","author":"Oosterveld","year":"2020","journal-title":"Mov Disord Off J Mov Disord Soc."},{"key":"10.1016\/j.nbd.2021.105311_bb0150","article-title":"Association of serum neurofilament light (sNfL) and disease severity in patients with spinocerebellar ataxia type 3","volume":"14","author":"Peng","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nbd.2021.105311_bb0155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.nbd.2021.105311_bb0160","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/acn3.504","article-title":"Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2","volume":"5","author":"Reetz","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"issue":"6","key":"10.1016\/j.nbd.2021.105311_bb0165","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S1474-4422(20)30143-5","article-title":"Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington\u2019s disease young adult study (HD-YAS): a cross-sectional analysis","volume":"19","author":"Scahill","year":"2020","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.nbd.2021.105311_bb0170","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","article-title":"Scale for the assessment and rating of ataxia: development of a new clinical scale","volume":"66","author":"Schmitz-H\u00fcbsch","year":"2006","journal-title":"Neurology."},{"issue":"7650","key":"10.1016\/j.nbd.2021.105311_bb0175","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature22044","article-title":"Antisense oligonucleotide therapy for spinocerebellar ataxia type 2","volume":"544","author":"Scoles","year":"2017","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.nbd.2021.105311_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-012-1000-x","article-title":"Brain pathology of spinocerebellar ataxias","volume":"124","author":"Seidel","year":"2012","journal-title":"Acta Neuropathol (Berl)."},{"issue":"7","key":"10.1016\/j.nbd.2021.105311_bb0185","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jmedgenet-2013-102200","article-title":"Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6","volume":"51","author":"Tezenas du Montcel","year":"2014","journal-title":"J. Med. Genet."},{"issue":"5","key":"10.1016\/j.nbd.2021.105311_bb0190","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.nbd.2021.105311_bb0195","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1007\/s00415-018-8893-9","article-title":"Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study","volume":"265","author":"Wilke","year":"2018","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.nbd.2021.105311_bb0200","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/acn3.583","article-title":"Serum neurofilament light chain is increased in hereditary spastic paraplegias","volume":"5","author":"Wilke","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"issue":"7","key":"10.1016\/j.nbd.2021.105311_bb0205","doi-asserted-by":"crossref","first-page":"e11803","DOI":"10.15252\/emmm.201911803","article-title":"Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice","volume":"12","author":"Wilke","year":"2020","journal-title":"EMBO Mol Med."},{"key":"10.1016\/j.nbd.2021.105311_bb0210","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3389\/fncel.2018.00366","article-title":"Plasma markers of Neurodegeneration are raised in Friedreich\u2019s Ataxia","volume":"12","author":"Zeitlberger","year":"2018","journal-title":"Front. Cell. Neurosci."},{"issue":"9","key":"10.1016\/j.nbd.2021.105311_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-2182-0","article-title":"CHIP as a therapeutic target for neurological diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Cell Death Dis."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996121000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996121000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:24:10Z","timestamp":1760851450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996121000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":43,"alternative-id":["S0969996121000607"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2021.105311","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2021.105311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105311"}}